THE FIRST GENERATION AND SECOND-GENERATION ANTIPSYCHOTIC DRUGS AND THEIR PHARMACOLOGY IN TREATMENT OF SCHIZOPHRENIA

Authors

  • Afroj Ayyaj Shaikh Hon Shri Babanrao Pachpute Vichardhara Trusts Group of Institutions
  • Jaydeep Pawar Hon. Shri. Babanrao Pachpute Vichardhara Trust, Group of Institution, Faculty of Pharmacy, Kashti

DOI:

https://doi.org/10.55766/sujst-2023-06-e0828

Keywords:

Antipsychotics, Ayurvedic Treatments, Brahmyadiyoga, Mental Disorder, Psychosis, Schizophrenia

Abstract

Schizophrenia is a complex and severe psychiatric disorder that affects millions of people worldwide. Antipsychotic drugs have been widely used for the treatment of schizophrenia for over 60 years. The first-generation antipsychotic drugs (FGAs) were introduced in the 1950s and revolutionized the treatment of schizophrenia. However, their use is associated with a number of adverse effects, including Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia (TD). Second-generation antipsychotic drugs (SGAs), also known as atypical antipsychotics, were developed in the 1990s and have become the preferred treatment for schizophrenia due to their lower incidence of EPS and TD. They also have a broader range of therapeutic effects, such as improving negative symptoms and cognitive impairment associated with schizophrenia. This review article summarizes the pharmacology of both FGAs and SGAs, including their mechanism of action, pharmacokinetics, and adverse effects. The efficacy and safety of these drugs in the treatment of schizophrenia are also discussed. In addition, this review examines the controversy surrounding the use of SGAs and their potential metabolic side effects, such as weight gain, hyperlipidemia, and diabetes. Despite the availability of SGAs, FGAs still have a role in the treatment of schizophrenia, particularly for patients who are unresponsive to SGAs or experience intolerable side effects. Furthermore, research continues to identify new pharmacological targets and treatment strategies for schizophrenia. Understanding the pharmacology and clinical use of antipsychotic drugs is essential for optimizing the treatment of schizophrenia and improving patient outcomes.

References

Atypical Antipsychotics. (2018). Physiopedia Physiopedia. Retrieved From: https://www.drugs.com/drug-class/atypical-antipsychotics.html?condition_id=94#filterSection

Bouchette, D., Fariba, K., and Marwaha, R. (2021). Ziprasidone. Treasure Island (FL): StatPearls Publishing. Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK448157/#!po=68.5185

Cardoso, D., Wakeham, J., Shaw, P.A., Dutton, B., and Wildman, L. (2017). Chlorpromazine verses thiothixene for people with schizophrenia. Cochrane database of systematic reviews, (9). https://doi.org/10.1002/14651858.CD012790

Chauhan, A., Mittal, A., and Arora, P.K. (2013). Atypical Antipsychotics from Scratch to the Present. International Journal of Pharamaceutical Sciences and Research, 4(1):184-204. Retrieved From: https://www.researchgate.net/publication/236875084_Atypical_Antipsychotics_from_Scratch_to_the_Present

Chokhawala, K. and Stevens, L. (2021). Antipsychotic Medications. StatPearls Publishing, Treasure Island (FL). Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK51950/#_article-17709_s3_

Citrome, L. (2011). Iloperidone: A Clinical Overview. The Journal of Clinical Psychiatry, 72(suppl 1):19-23. https://doi.org/10.4088/JCP.10075su1.04

Collins, P. (2019). Psychological debriefing - are we doing more harm than good?. Retrieved From: blueline.ca: https://www.blueline.ca/psychological-debriefing-are-we-doing-more-harm-than-good-6321/

Din, L. and Preuss, C.V. (2021). Prochlorperazine. Treasure Island (FL): StatPearls Publishing. Retrieved From: wikipedia.org: https://www.ncbi.nlm.nih.gov/books/NBK537083#!po=91.9355

Farah, H.F. (2018). Schizohrenia: An Overview. Asian Journal of Pharmaceutics, 12(2):77-87. Retrieved From: https://www.researchgate.net/publication/326922790_Schizophrenia_An_Overview

First versus second generation. (2021). Retrieved From: https://www.library.neura.edu.au/schizophrenia/treatment/physical/pharmaceutical/second-generation-antipsychotics/first-versus-second-generation/

Gardner, D.M. (2005). Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal, 172(13):1,703-1,711. https://doi.org/10.1503/cmaj.1041064

Gettu, N. and Saadabadi, A. (2021). Aripiprazole. In A. Saadabadi (Ed.). Treasure Island (FL): StatPearls Publishing. Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK547739

Haddad, P., Kirk, R., and Green, R. (2016). Chlopromazine, the first antipsychotic medication: history, controversy and legacy. British association for Psychopharmacology. Retrieved From: https://www.bap.org.uk/articles/chlorpromazine-the-first-antipsychotic/

Harvey, R.A., Clark, M.A., Finkel, R., Rey, J.A., and Whalen, K. (2011). Lippincott’s Illustrated Reviews: Pharmacology (5th ed.). New York: WoltersKluwer.

How Schizophrenia is Diangnosid by Observing Symptoms. (2021). Retrieved From: https://www.verywellmind.com/what-are-the-symptoms-of-schizophrenia-2953120.

John, L. and Maccabe, J.H. (2015). Antipsychotic medication in schizophrenia: a review. British Medical Bulletin, 114(1):169-179. https://doi.org/10.1093/bmb/ldv017

Kane, J.M. (2011). Lurasidone: A Clinical Overview. The Journal of Clinical Psychiatry, 72(suppl 1):24-28. https://doi.org/10.4088/JCP.10075su1.05

Kaur, H., Kaur, R., Rani, V., Sharma, K., and Maurya, P. (2020). Antipsychotic Drugs. 1st Ed. In Advances in Neuropharmacology: Drugs and Therapeutics, 297-316p. https://doi.org/10.1201/9780429242717-15

Khan, Z.U., Montanez, E.M., and Muly, E.C. (2013). Schizophrenia: Causes and Treatments. Current Pharmaceutical Design, 19(36):6,451-6,461. https://doi.org/10.2174/1381612811319360006

Kirkpatrick, B., Miller, B., Garcia-Rizo, C., and Fernandez-Egea, E. (2014). Schizophrenia. Clinical Schizophrenia & Realated Psychoses, 8(2):1-13. https://doi.org/10.3371/CSRP.KIMI.031513

Laszlovszky, I., Barabassy, A., and Nemeth, G. (2021). Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy, 38(1):3,652-3,673. https://doi.org/10.1007/s12325-021-01797-5

Leucht, S.C. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (London, England), 373(9657):31-41. https://doi.org/10.1016/S0140-6736(08)61764-X

List of antipsychotics - generics only. (2021). Retrieved From: https://www.drugs.com/drug-class/antipsychotics.html

Maan, J.S., Ershadi, M., Khan, I., and Saadabadi, A. (2021). Quetiapine. Treasure Island (FL): StatPearls. Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK459145/#_NBK459145_pubdet_

Mann, S.K. and Marwaha, R. (2021). Chlorpromazine. Treasure Island (FL): StatPearls Publishing. Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK553079/

McNeil, S.E., Gibbons, J.R., and Cogburn, M. (2021). Risperidone. Treasure Island (FL): StatPearls Punlishing. Retrieved From: https://www.ncbi.nim.nih.gov/books/NBK459313/#_NBK459313_pubdet_

Meltzer, H.Y. (2013). Update on typical and atypical antipsychotic drugs. Annual review of medicine, 64:393-406. https://doi.org/10.1146/annurev-med-050911-161504

NCATS Inxight Drugs - THIORIDAZINE. National Center for Advancing Translational Sciences. (n.d.). Retrieved From: drugs.ncats.io: https://drugs.ncats.io/subtance/N3D6TG58NI

Nerkar, A. G., and Bhise, S. B. (2019). Schizophrenia: A Review. Current Trends in Pharmacy and Pharmacuetical Chemistry, 1(4):1-9. Retrieved From: https://e-currentscience.com/journal/e/CTPPC

Nerkar, A.G. and Bhise, S.B. (2020). Polypharmacological Drugs in Treatment of Schizophrenia. Current Trends in Pharmacy and Pharmaceutical Chemistry, 2(3):116-124.

Ozeki, Y.F., Ozeki, Y., Fujii, K., Kurimoto, N., Yamada, N., Okawa, M., Aoki, T., Takahashi, J., Ishida, N., Horie, M., and Kumugi, H. (2010). QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 34(2):401-405. https://doi.org/10.1016/j.pnpbp.2010.01.008

Patel, K.R., Cherian, J., Gohil, K., and Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. P & T: a peer-reviewed journal for formulary management, 39(9):638-645. Retrieved From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159061/#!po=0.632911

Physiopedia. (2020). Clozapine in the Treatment of Psychosis. Retrieved From: https://www.physio-pedia.com/index.php?title=Clozapine_in_the_Treatment_of_Psychosis&oldid=228645

pimozide (Rx). (2021). Retrieved From: https://web.archive.org/web/20131204215602/https://reference.medscape.com/drug/orap-pimozide-34982#10

Popovic, D., Nuss, P., and Vieta, E. (2015). Revisiting loxapine: A systematic review. Annals of General Psychiatry, 14(15):1-8. https://doi.org/10.1186/s12991-015-0053-3

Rahman, S. And Marwaha, R. (2021). Haloperidol. Tresaure Island (FL): StatPearls Publishing. Retrieved From: https://www.ncbi.nim.nih.gov/books/NBK560892/#_NBK560892_pubdet_

Rasool, S., Zeeshan, Zafar, Ali, Z., and Erum, A. (2018). Schizophrenia: An overview. Clinical Practice, 15(5):847-851. https://doi.org/10.4172/clinical-practice.1000417

Schizophrenia Symptoms: Positive and Negative Symptoms Explaind. (2020). Retrieved From: https://www.webmd.com/schizophrenia/schizophrenia- symptoms

Schizophrenia. (2019). World Health Organization (WHO). Retrieved From: https://www.who.int/news-room/fact-sheets/detail/schizophrenia#:~:text=Schizophrenia%20affects%20approximately%2024%20million,as%20many%20other%20mental%20disorders.

Schizophrenia. (2020). (U.S. Department of Health and Human Services) Retrieved May 2023, from National Institute of Mental Health: https://www.nimh.nih.gov/health/topics/schizophrenia

Simpson, E.H., Kellendonk, C., and Kandel, E. (2010). A Possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron, 65(5):585-596. https://doi.org/10.1016/j.neuron.2010.02.014

Siragusa, S., Bistas, K.G., and Saadabadi, A. (2021). Fluphenazine. Treasure Island (FL): StatPearls Publishing. Retrieved From: https://www.mcbi.nlm.nih.gov/books/NBK459194/

Steven, G. and Potkin. (2011). Asenapine: A Clinical Overview. The Journal of Clinical Psychiatry, 72(suppl 1):14-18. https://doi.org/10.4088/JCP.10075su1.03

Thomas, K. and Saadabadi, A. (2021). Olanzapine. Treasure Island (FL): StatPearls Publishing. Retrieved From: https://www.ncbi.nlm.nih.gov/books/NBK532903/

Trifluoperazine. (n.d.). Retrieved From: https://en.m.wikipedia.org/wiki/Trifluoperazine

Volkan, K. (2020). Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology and Treatment. Journal of Health and Medical Sciences, 3(4):487-521. https://doi.org/10.31014/aior.1994.03.04.143

Zhang, L., Li, J., Zhao, Y., Su, Y., and Tianmei, S. (2016). Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatric Disease and Treatment, 12:113-131. https://doi.org/10.2147/NDT.S64672

Downloads

Published

2024-02-05

How to Cite

Ayyaj Shaikh, A., & Pawar, J. (2024). THE FIRST GENERATION AND SECOND-GENERATION ANTIPSYCHOTIC DRUGS AND THEIR PHARMACOLOGY IN TREATMENT OF SCHIZOPHRENIA. Suranaree Journal of Science and Technology, 30(6), 070068(1–9). https://doi.org/10.55766/sujst-2023-06-e0828